PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Glenn D. Prestwich to Speak At 7th Modern Drug Discovery Summit October 19-21 in San Diego, California - Glenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of University of Utah, will give a presetation at this conference - GTCbio.com
Glenn D. Prestwich to Speak At 7th Modern Drug Discovery Summit October 19-21 in San Diego, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/08/31 - Glenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of University of Utah, will give a presetation at this conference - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Glenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of Medicinal Chemistry at
University of Utah, will give a plenary keynote presentation on “Engineering a Clinical Biomaterial for Regenerative Medicine: From Bench to Business” at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC.

Faculty entrepreneurism is a scholarly activity. Dr. Prestwich will describe how the University of Utah has implemented policies that encourage faculty and student entrepreneurial activities through the Entrepreneurial Faculty Scholars and the Young Entrepreneurial Student Scholars programs. He will also describe a case study for commercialization of a university technology in the area of regenerative medicine.

Dr. Prestwich will also discuss how they created a synthetic extracellular matrix (sECM) from hyaluronic acid (HA) that affords highly reproducible, manufacturable, approvable, and affordable biomaterials. The in situ crosslinkable sECM hydrogels can be customized for use with progenitor and mature cell populations obtained many tissues, including skin, fat, liver, heart, brain, muscle, bone, and cartilage. In addition, sECMs have been developed for rapid expansion and recovery of cells in 3-D, and for the bioprinting of engineered tissue constructs. The technology is being commercialized in three fields of use: human medical devices, cell therapy and research tools for 3-D cell culture, and veterinary wound care and adhesion prevention.

Dr. Glenn D. Prestwich’s passion for translational research and scholarship led to his appointment as director of the Entrepreneurial Faculty Scholars program at the U of Utah (2008 – current). He has launched over seven small life science companies in the last fifteen years: Clear Solutions Biotech (1994-2001); Echelon Biosciences, Inc. (CSO, 1997-2003); Sentrx Surgical, Inc. (CSO, 2003-2004); Carbylan BioSurgery, Inc. (Palo Alto, CA)(2004-current); Sentrx Animal Care, Inc. (Salt Lake City)(2005-current); Glycosan BioSystems, Inc. (Salt Lake City) (CSO, 2005-2011); GlycoMira, Inc. (CSO, Salt Lake City) (2008 - current); Metallosensors (CEO, 2011 – current). He is a Scientific Advisor for Novozymes, Elastin Specialities, ContraDyn, Organonovo, Brickell Biotech, and OrthoCyte/BioTime. He received the Governor’s Medal for Science and Technology for 2006, was awarded the 1998 Paul Dawson Biotechnology Award and the 2008 Volwiler Research Award of the American Association of Colleges of Pharmacy. In 2010, he received the University of Utah Distinguished Scholarly and Creative Research Award, as well as the 2010 “Rooster Prize” of the International Society for Hyaluronan Science for outstanding contributions to hyaluronan-derived products. During his 33 years as a faculty member, he has published over 600 technical papers, patents, and book chapters, and has trained over 125 postgraduate scientists. In 2011, he was invited to serve as a member of the editorial advisory board for Science Translational Medicine. His university research programs included (i) new reagents for lipid signaling in cell biology and cancer treatment, (ii) biomaterials for wound repair, cartilage repair, tissue engineering, scar-free healing, and toxicology and xenograft models, and (iii) sulfated glycosaminoglycan analogues as inflammation modulators for clinical use.

The 7th Modern Drug Discovery and Development Summit will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. Over 125 leading industrial and academic experts will present at this three-day summit and is comprised of a half day plenary keynote session and 4 full conferences. The M3D Summit includes the following conferences:

5th Biomarker Discovery and Development
5th Drug Design and Medicinal Chemistry
5th Advances in Stem Cell Discovery and Development
4th Protein Discovery & Therapeutics

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Glenn D. Prestwich to Speak At 7th Modern Drug Discovery Summit October 19-21 in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)